2024
Life's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, Hawkes M, de Havenon A, Schwamm L, Sheth K, Gill T, Falcone G. Life's Essential 8 and Poor Brain Health Outcomes in Middle-Aged Adults. Neurology 2024, 103: e209990. PMID: 39442069, PMCID: PMC11498939, DOI: 10.1212/wnl.0000000000209990.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrainCardiovascular DiseasesDementiaDepressionFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedProspective StudiesRisk FactorsStrokeUnited KingdomUnited StatesConceptsLife's Essential 8Poor cardiovascular healthCardiovascular healthBrain healthLife's Essential 8 scoreUnadjusted riskEssential 8Determinants of cardiovascular healthUK Biobank (UKBCardiovascular health profileModifiable cardiovascular risk factorsBrain health outcomesRisk factorsComposite outcomePublic health constructsPopulation studiesMiddle-aged adultsCox modelLate-life depressionCox proportional hazards modelsBrain health benefitsMultivariate Cox modelCardiovascular risk factorsFollow-up timeAoU participants
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2021
Midlife Blood Pressure Variability and Risk of All-Cause Mortality and Cardiovascular Events During Extended Follow-up
de Havenon A, Delic A, Yaghi S, Wong KH, Majersik JJ, Stulberg E, Tirschwell D, Anadani M. Midlife Blood Pressure Variability and Risk of All-Cause Mortality and Cardiovascular Events During Extended Follow-up. American Journal Of Hypertension 2021, 34: 1269-1275. PMID: 34240111, PMCID: PMC8643578, DOI: 10.1093/ajh/hpab106.Peer-Reviewed Original ResearchMeSH KeywordsBlood PressureBlood Pressure DeterminationCardiovascular DiseasesFollow-Up StudiesHumansHypertensionMyocardial InfarctionRisk FactorsConceptsBlood pressure variabilityLong-term blood pressure variabilityCardiovascular eventsHazard ratioPressure variabilityCardiovascular disease-free participantsMean systolic blood pressureVisit blood pressure variabilityCox proportional hazards modelCardiovascular risk factorsCorresponding hazard ratiosCongestive heart failureDisease-free patientsSystolic blood pressureDisease-free participantsProportional hazards modelPrior strokeCause mortalitySecondary outcomesBlood pressureHeart failureIndependent predictorsPrimary outcomeVisit 4Mean ageWhite Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial
Sheibani N, Wong KH, Turan TN, Yeatts SD, Gottesman RF, Prabhakaran S, Rost NS, de Havenon A. White Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial. Journal Of Stroke And Cerebrovascular Diseases 2021, 30: 105764. PMID: 33823461, PMCID: PMC8107132, DOI: 10.1016/j.jstrokecerebrovasdis.2021.105764.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialWhite matter hyperintensity volumeSystolic blood pressurePrimary outcomeHazard ratioLog-transformed white matter hyperintensity volumeGoal systolic blood pressureLog-transformed continuous variableComposite of strokeIntensive BP loweringHigh cardiovascular riskAcute coronary syndromeCongestive heart failureProspective clinical trialsCardiovascular disease outcomesFuture CVD riskWhite matter hyperintensitiesSubset of participantsBP loweringCardiovascular deathCardiovascular eventsCoronary syndromeCardiovascular riskCVD riskBlood pressure